Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

Firm announcement No. 13 / 2026

Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program

• Strong money place of USD 2.3 billion (DKK 14.5 billion) as of March 31, 2026
• Monetary power to be additional enhanced by important milestone funds of USD 700 million from Roche in 2026
• Persevering with to speculate considerably in analysis capabilities to construct a number one metabolic well being pipeline and execute on Metabolic Frontier 2030 technique

Copenhagen, Denmark, Might 7, 2026 – Zealand Pharma A/S (“the Firm” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology firm reworking the way forward for metabolic well being, right this moment pronounces that it has determined to provoke a share buy-back program (the “Program”), beneath which the Firm will purchase again personal shares for a most whole consideration of DKK 1.3 billion  and a most of seven,152,557 shares. The Program will run from Might 7, 2026, as much as and together with October 31, 2026, except it’s terminated or suspended earlier by the Firm. Danske Financial institution will act as lead supervisor and, at its discretion, could full the Program previous to the top of the said interval. The Program will probably be carried out in accordance with Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Fee Delegated Regulation (EU) 2016/1052 (the “Secure Harbour Regulation”).

“Zealand Pharma’s robust steadiness sheet permits us to execute on our key strategic priorities – maximize the worth of petrelintide, speed up and strengthen our analysis engine, and leverage exterior innovation to reinforce R&D capabilities, whereas preserving ample room for returning capital to shareholders”, stated Henriette Wennicke, Govt Vice President, Chief Monetary Officer.  “Our robust monetary place and outlook, pushed by constructive developments for our main weight problems packages, present us with the flexibleness to execute on all of those goals.”

In 2026, Zealand Pharma expects to obtain milestone funds of USD 700 million from Roche, together with USD 575 million linked to the initiation of Part 3 trials with petrelintide monotherapy, anticipated within the second half of 2026, and an anniversary fee of USD 125 million in Q2 2026.

Function and key phrases
The Program will probably be based mostly on the prevailing authorization granted to the Board of Administrators by the Annual Common Assembly in March 2026 to accumulate treasury shares.  Underneath this authorization, the Firm could repurchase shares available in the market, supplied that the Firm’s combination holdings of treasury shares don’t at any time exceed a complete nominal worth of 10% of the Firm’s share capital. Moreover, pursuant to the authorization, the acquisition value for such treasury shares could not deviate by greater than 10% from the quoted value of the Firm’s shares on Nasdaq Copenhagen on the time of acquisition.

The aim of the Program is to (i) meet obligations arising from the Firm’s share-based incentive packages and (ii) scale back the share capital (doubtlessly via subsequent cancellation of shares repurchased, topic to any obligatory extra company resolutions), as relevant.
The Program will probably be carried out in accordance with MAR and the “Secure Harbour Regulation and be topic to the constraints beneath the important thing phrases of the Program beneath.

The Firm has appointed Danske Financial institution as lead supervisor for the Program. Danske Financial institution will make its personal buying and selling selections independently of, and with out affect from, the Firm, inside the phrases of the Program as introduced beneath and in accordance with relevant regulation.

Key phrases of the Program
The Program will start on Might 7, 2026 and be accomplished no later than October 31, 2026 except it’s terminated or suspended earlier by the Firm. Additional, Danske Financial institution could, at its discretion, full the Program previous to the top of the said interval.

The Program will probably be carried out beneath the next framework:

• The utmost whole consideration for shares purchased again beneath the Program is DKK 1.3 billion.
• The utmost variety of shares which may be acquired beneath the Program is 7,152,557.
• Purchases will probably be carried out on Nasdaq Copenhagen.
• Shares might not be bought at a value exceeding the upper of: (i) the worth of the final impartial transaction on the buying and selling venue the place the acquisition is carried out and (ii) the very best present impartial bid on that buying and selling venue on the time of buy. The shares might not be acquired at a value deviating greater than 10% from the worth quoted on Nasdaq Copenhagen A/S on the time of acquisition.
• The utmost variety of shares which may be purchased on any single buying and selling day is not going to exceed 25% of the typical every day buying and selling quantity of the Firm’s shares on the related buying and selling venue, based mostly on the typical every day quantity throughout the previous 20 buying and selling days.
• The Firm could droop or terminate the Program at any time. Any such resolution will probably be disclosed in an organization announcement.
• On a weekly foundation, the Firm will subject an organization announcement in respect of transactions made beneath the Program (in accordance with relevant necessities)

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology firm centered on advancing medicines for weight problems and metabolic well being. Combining greater than 25 years of peptide R&D experience with a proprietary information platform that leverages superior information pushed and AI/ML approaches, Zealand Pharma goals to steer a brand new period in weight problems and metabolic well being. Up to now, greater than 10 Zealand Pharma invented drug candidates have entered scientific improvement, of which two merchandise have reached the market and three candidates are in late-stage improvement. The Firm has collaborations with world pharmaceutical and biotechnology companions for analysis, improvement, and commercialization. Based in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Study extra at www.zealandpharma.com.

Contacts
Eric Rojas (Buyers)
Vice President, Head of Investor Relations
Zealand Pharma
E mail: erojas@zealandpharma.com

Adam Lange (Buyers)
Vice President, Investor Relations
Zealand Pharma
E mail: alange@zealandpharma.com

Neshat Ahmadi (Buyers)
Investor Relations Supervisor
Zealand Pharma
E mail: neahmadi@zealandpharma.com

Rachel James-Owens (Media)
Vice President, Company Communications and Media Relations
Zealand Pharma
E mail: rjamesowens@zealandpharma.com

Andreas Hylleberg Mølleskov (Media) 
Director, Exterior Communications
Zealand Pharma
E mail: ahylleberg@zealandpharma.com